Suppr超能文献

人抗血友病因子的延长稳定性和无菌性

Extended Stability and Sterility of Antihemophilic Factor Human.

作者信息

Shields Sarah, Kim Abby, Elder Joshua

出版信息

J Pediatr Pharmacol Ther. 2017 May-Jun;22(3):203-206. doi: 10.5863/1551-6776-22.3.203.

Abstract

OBJECTIVES

Antihemophilic factor human is a factor VIII product used to supplement those with hemophilia. Recent data show treatment benefit and cost saving opportunities if factor products are administered as a continuous infusion rather than conventional bolus dose. This method has not been widely used given the lack of evidence for safe and effective use beyond 3 hours from preparation. The objectives of this study were to determine the physical and chemical stability and sterility of antihemophilic factor human over a 7-day period.

METHODS

Antihemophilic factor human was obtained from the manufacturer. Baseline stability and sterility were determined by factor activity levels along with bacterial and fungal cultures. These tests were also evaluated over a span of 7 days at room temperature and under refrigeration.

RESULTS

Each sample was inspected at the time of delivery and showed no visible signs of physical changes. Factor activity levels were maintained between 88% and 102% of baseline measurements. No growth was observed for bacterial or fungal cultures in any sample after 4 weeks of incubation.

CONCLUSIONS

Antihemophilic factor human maintained physical stability and chemical stability and remained sterile for the 7-day period, allowing extended stability and continuous infusions to be considered.

摘要

目的

重组人凝血因子 VIII 是一种用于补充血友病患者凝血因子的产品。近期数据表明,若以持续输注而非传统大剂量推注的方式给药,凝血因子产品不仅能带来治疗益处,还能节省成本。鉴于缺乏制备后超过3小时安全有效使用的证据,这种方法尚未得到广泛应用。本研究的目的是确定重组人凝血因子 VIII 在7天内的物理化学稳定性和无菌性。

方法

从制造商处获取重组人凝血因子 VIII。通过因子活性水平以及细菌和真菌培养来确定基线稳定性和无菌性。这些测试还在室温及冷藏条件下进行了为期7天的评估。

结果

每个样品在交付时进行检查,未发现明显的物理变化迹象。因子活性水平维持在基线测量值的88%至102%之间。培养4周后,任何样品的细菌或真菌培养均未观察到生长。

结论

重组人凝血因子 VIII 在7天内保持了物理稳定性和化学稳定性,且仍保持无菌,这使得延长稳定性和持续输注成为可能。

相似文献

1
Extended Stability and Sterility of Antihemophilic Factor Human.
J Pediatr Pharmacol Ther. 2017 May-Jun;22(3):203-206. doi: 10.5863/1551-6776-22.3.203.
2
Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration.
Am J Hematol. 1999 Sep;62(1):13-8. doi: 10.1002/(sici)1096-8652(199909)62:1<13::aid-ajh3>3.0.co;2-x.
4
Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
Blood Coagul Fibrinolysis. 2006 Apr;17(3):165-71. doi: 10.1097/01.mbc.0000220236.92219.08.
7
Analysis of 72-hour sterility of common pediatric continuous intravenous infusions.
J Pediatr Pharmacol Ther. 2009 Jan;14(1):25-31. doi: 10.5863/1551-6776-14.1.25.
8
Antihemophilic factor (factor VIII).
Ann Intern Med. 1978 Mar;88(3):403-9. doi: 10.7326/0003-4819-88-3-403.
9
Sterility and Stability Testing of Preservative-free Albuterol.
J Pediatr Pharmacol Ther. 2019 Jan-Feb;24(1):53-57. doi: 10.5863/1551-6776-24.1.53.

引用本文的文献

1
Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.
TH Open. 2020 Nov 6;4(4):e354-e361. doi: 10.1055/s-0040-1719082. eCollection 2020 Oct.

本文引用的文献

1
Guidelines for the management of hemophilia.
Haemophilia. 2013 Jan;19(1):e1-47. doi: 10.1111/j.1365-2516.2012.02909.x. Epub 2012 Jul 6.
2
A study of variations in the reported haemophilia A prevalence around the world.
Haemophilia. 2010 Jan;16(1):20-32. doi: 10.1111/j.1365-2516.2009.02127.x. Epub 2009 Oct 21.
3
In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
Haemophilia. 2010 Jan;16(1):72-9. doi: 10.1111/j.1365-2516.2009.02103.x. Epub 2009 Sep 17.
6
7
Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery.
Br J Haematol. 2000 Sep;110(3):715-20. doi: 10.1046/j.1365-2141.2000.02226.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验